|
|
 |
|
Viewing report
|
|
|
|
Injectable Generic Drugs: Prospects & Opportunities to 2013
Espicom Business Intelligence Ltd, Dec 2009, Pages: 318
This market leading strategic analysis from Espicom provides the market context for injectable generic drugs, individual analysis of 55 leading therapies and evaluation of 19 companies active in the sector. Key therapy sectors include cancer, CNS, cardiovascular, anti-infectives, diabetes, growth disorders and inflammatory conditions.
For more than half of the injectable generics approved in recent years, just one or two manufacturers have received ANDA approvals and 86% of molecules have fewer than five generic competitors
The generic industry is known for producing ‘affordable medicines’. Cost has been an important factor in their development, particularly for oral drugs that are relatively cheap to produce and can be introduced to the market at a fraction of the price of the original drugs. As the generic industry matures however, companies are increasingly looking towards alternative drug delivery technologies as a route to a competitive edge in a crowded market.
A changing corporate landscape
The continuing importance of the injectable generic sector is evidenced by the ongoing developments in the corporate landscape. Pfizer’s agreements with Aurobindo and Claris Lifesciences have been strengthened and Novartis’ acquisition of Ebewe has improved Sandoz’s access to injectable products. Akorn Strides and Fresenius Kabi are new names to the top flight, with the latters acquisition of Dabur and APP putting it in a strong position in the US.
A biosimilar future
Generic manufacturers are beginning to look towards a biosimilar market for future growth. While several biosimilars have now been approved in the EU, a viable regulatory process has yet to be approved in the US. A biosimilar regulation is now more or less agreed as part of President Obama’s general health reform bill, but it remains to be seen whether or not this will be passed. Despite the hurdles, for those companies with the capability to produce biologicals, and the money to invest in their development, there is enormous potential in this high-value market.
This report provides…
- Individual analysis of 55 leading therapies
- Product forecasts by value 2009/2014
- Comprehensive patent information by product and expiry date
- The market context for injectable drugs
- Evaluation of 19 companies competing in the sector
- Analysis of significant litigation
Key therapy sectors covered...
- Cancer
- CNS
- Cardiovascular
- Anti-Infectives
- Diabetes
- Growth Disorders
- Anti-inflammatory
|
|
|
|
